182 related articles for article (PubMed ID: 36950852)
1. SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta-analysis of randomized clinical trials.
Oates CP; Santos-Gallego CG; Smith A; Basyal B; Moss N; Kawamura I; Musikantow DR; Turagam MK; Miller MA; Whang W; Dukkipati SR; Reddy VY; Koruth JS
J Cardiovasc Electrophysiol; 2023 May; 34(5):1277-1285. PubMed ID: 36950852
[TBL] [Abstract][Full Text] [Related]
2. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials.
Sfairopoulos D; Zhang N; Wang Y; Chen Z; Letsas KP; Tse G; Li G; Lip GYH; Liu T; Korantzopoulos P
Europace; 2022 Jan; 24(1):20-30. PubMed ID: 34333592
[TBL] [Abstract][Full Text] [Related]
3. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials.
Fernandes GC; Fernandes A; Cardoso R; Penalver J; Knijnik L; Mitrani RD; Myerburg RJ; Goldberger JJ
Heart Rhythm; 2021 Jul; 18(7):1098-1105. PubMed ID: 33757845
[TBL] [Abstract][Full Text] [Related]
4. Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i-Arrhythmias and Sudden Cardiac Death).
Liao J; Ebrahimi R; Ling Z; Meyer C; Martinek M; Sommer P; Futyma P; Di Vece D; Schratter A; Acou WJ; Zhu L; Kiuchi MG; Liu S; Yin Y; Pürerfellner H; Templin C; Chen S
Cardiovasc Diabetol; 2024 Feb; 23(1):78. PubMed ID: 38402177
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
[TBL] [Abstract][Full Text] [Related]
6. Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials.
Sfairopoulos D; Liu T; Zhang N; Tse G; Bazoukis G; Letsas K; Goudis C; Milionis H; Vrettos A; Korantzopoulos P
Heart Fail Rev; 2023 Jul; 28(4):925-936. PubMed ID: 36282460
[TBL] [Abstract][Full Text] [Related]
7. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors.
Scheen AJ
Diabetes Metab; 2022 Nov; 48(6):101405. PubMed ID: 36334794
[TBL] [Abstract][Full Text] [Related]
8. Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials.
Zheng S; Lai Y; Jiang C; He L; Zhao Z; Li W; Tang R; Sang C; Long D; Du X; Ma C; Dong J
Pacing Clin Electrophysiol; 2024 Jan; 47(1):58-65. PubMed ID: 38010824
[TBL] [Abstract][Full Text] [Related]
9. Effect of sodium glucose cotransporter 2 inhibitors on atrial tachy-arrhythmia burden in patients with cardiac implantable electronic devices.
Younis A; Arous T; Klempfner R; Kharsa A; McNitt S; Schleede S; Polonski B; Abdallah Z; Buttar R; Bodurian C; Tabaja C; Yavin HD; Shamroz F; Wazni OM; Wittlin SD; Aktas M; Goldenberg I
J Cardiovasc Electrophysiol; 2023 Aug; 34(8):1595-1604. PubMed ID: 37453072
[TBL] [Abstract][Full Text] [Related]
10. Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials.
Xu B; Kang B; Zhou J
Clin Res Cardiol; 2024 Jun; 113(6):910-923. PubMed ID: 38353684
[TBL] [Abstract][Full Text] [Related]
11. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis.
Chen J; Jiang C; Guo M; Zeng Y; Jiang Z; Zhang D; Tu M; Tan X; Yan P; Xu X; Long Y; Xu Y
Cardiovasc Diabetol; 2024 Jan; 23(1):2. PubMed ID: 38172861
[TBL] [Abstract][Full Text] [Related]
12. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials.
Li X; Zhang Q; Zhu L; Wang G; Ge P; Hu A; Sun X
Int J Cardiol; 2021 Jun; 332():119-126. PubMed ID: 33838152
[TBL] [Abstract][Full Text] [Related]
13. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
[TBL] [Abstract][Full Text] [Related]
15. No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials.
Al-Gobari M; Le HH; Fall M; Gueyffier F; Burnand B
PLoS One; 2017; 12(2):e0171168. PubMed ID: 28166237
[TBL] [Abstract][Full Text] [Related]
16. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
17. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S
ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512
[TBL] [Abstract][Full Text] [Related]
19. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
[TBL] [Abstract][Full Text] [Related]
20. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death.
Claro JC; Candia R; Rada G; Baraona F; Larrondo F; Letelier LM
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD008093. PubMed ID: 26646017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
